Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Nice – page 7

971 clinical trials in Nice, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nice at a glance
971
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

971 trials in Nice

Open in trial search

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Study of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Merck Sharp & Dohme LLC
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione
  • Sponsor:Pharming Technologies B.V.

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide

Bladder cancer

Recruiting

Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Nice

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on neurodegenerative conditions and movement disorders, including trials evaluating new treatments for Amyotrophic Lateral Sclerosis and Essential Tremor.

  • ALS Treatment Development
  • Movement Disorder Therapies
  • Multiple Sclerosis Management

Studies aim to improve quality of life and slow disease progression through targeted therapeutic approaches.

02 Autoimmune Conditions

Comprehensive research into inflammatory disorders, including studies on Psoriatic Arthritis and innovative treatments for various autoimmune conditions.

  • Psoriasis Management
  • Inflammatory Disease Therapy
  • Myasthenia Gravis Treatment

Focus on developing targeted therapies and combination treatments for better disease control.

03 Oncology Research

Advanced studies in cancer treatment, particularly focusing on head and neck cancers and innovative approaches in lung cancer therapy.

  • Head and Neck Cancer Treatments
  • Neuroendocrine Carcinomas
  • Prostate Cancer Therapy

Investigating combination therapies and targeted treatments for improved patient outcomes.

04 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, including novel approaches for Crohn's Disease and Ulcerative Colitis treatment.

  • Microbiota Transplantation
  • IBD Management
  • Novel Therapeutic Approaches

Exploring innovative therapeutic strategies and microbiome-based treatments.

05 Infectious Disease Prevention

Critical research in HIV prevention and treatment, focusing on long-acting preventive medications and innovative therapeutic approaches.

  • HIV Pre-Exposure Prophylaxis
  • Long-Acting Treatments
  • Prevention Strategies

Development of new preventive measures and treatment options for at-risk populations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.